Pharmacogenomics for stratified antidepressant treatment in major depressive disorder: evidence, limits and a roadmap for clinical use
Bernhard T Baune · 2026
Read Pharmacogenomics for stratified antidepressant treatment in major depressive disorder: evidence, limits and a roadmap for clinical use by Bernhard T Baune (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13374748.txt.
Description
Bernhard Baune reviews gene-guided choice of antidepressants for major depression. His twenty twenty-six review notes that care today runs by trial and error, though people vary a lot in drug levels and response. Gene tests promise a stratified path, picking drug and dose by body chemistry.
Current guides back gene-informed use for a few liver gene routes, most firmly CYP2D6 and CYP2C19. Two serotonin genes, by contrast, are not ready for clinic calls. Trials show gene guidance cuts mismatched prescribing more surely than it lifts mood in broad groups. The review closes with a road map: where testing helps now, where it may help subgroups, and what proof is still missing.
Catalog record
| CREATOR | Bernhard T Baune |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 50 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |